Latest Neuroblastoma Stories

--In Genome-Wide Study, Researchers at The Children's Hospital of Philadelphia Uncover New Clues to a Childhood Cancer-- PHILADELPHIA, Sept. 4, 2012 /PRNewswire-USNewswire/ -- Researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. Using automated technology to perform genome-wide association studies on DNA from thousands of subjects, the study broadens understanding of how gene changes may make a child susceptible to this early...

Funding Is Needed to Advance Research and Treatment to Cure Kids with Cancer Philadelphia, PA (PRWEB) September 02, 2012 The Children’s Hospital of Philadelphia launches 30 Days, 1 Cause, an advertising and social media campaign to bring the issue of funding for pediatric cancer research to the forefront as part of September’s Childhood Cancer Awareness Month. The 30 Days, 1 Cause campaign encourages the community to register for the Four Seasons Parkway Run/Walk, and learn how to...

A new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment. Researchers at The Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called crizotinib, which recently showed positive early results in its first trial in children with cancer. Crizotinib has already been licensed by the US Food and...

SAN DIEGO, July 5, 2012 /PRNewswire/ -- Little Benjamin Hess was only 3 years old when his mother noticed his eyelids were drooping, and he had developed dark circles under his eyes. When she took him to his pediatrician in Sydney, Australia, the doctor ordered several tests, and Benji was diagnosed with neuroblastoma, a rare childhood cancer. After weeks of research Benji's mom opted to travel to Mexico for treatment. According to TMD Limited, a medical tourism research company,...

On June 23, 2012, the Matthew Bittker Foundation will present the Children’s Hospital of Michigan Foundation (CHM Foundation) with a check for $50,000 to advance the research and treatment for children diagnosed and/or treated with neuroblastoma at the DMC Children’s Hospital of Michigan. Detroit, Michigan (PRWEB) June 21, 2012 On June 23, 2012, the Matthew Bittker Foundation will present the Children’s Hospital of Michigan Foundation (CHM Foundation) with a check for $50,000 to...

QUÉBEC CITY, June 21, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues. Data were presented yesterday by Brian H. Kushner, MD, of...

HOUSTON, June 18, 2012 /PRNewswire-USNewswire/ -- Dr. Eugene Kim, a pediatric surgeon with Texas Children's Cancer Center and assistant professor of surgery at Baylor College of Medicine (BCM), and Dr. Jason Shohet, chair of the Neuroblastoma Research Program at Texas Children's Cancer Center and associate professor in the Section of Hematology-Oncology at BCM, will speak at the Advances in Neuroblastoma Research (ANR) conference about the identification of a novel stem cell...

QUÉBEC CITY, June 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Brian H. Kushner, MD, of the Memorial Sloan-Kettering Cancer Center in New York, will be making a poster presentation on Phase 1 results for perifosine in neuroblastoma, at the Advances in Neuroblastoma Research Conference which will be held June 18-21, 2012, at the Fairmount Royal York Hotel in Toronto. "Targeting PI3K/Akt...

CINCINNATI, June 12, 2012 /PRNewswire-USNewswire/ -- An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma - a deadly, hard-to-cure childhood cancer. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) The experimental radiopharmaceutical, 131I-MIBG, has already been tested in children with relapsed and resistant neuroblastoma,...

An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma – a deadly, hard-to-cure childhood cancer. The experimental radiopharmaceutical, 131I-MIBG, has already been tested in children with relapsed and resistant neuroblastoma, with encouraging results in reducing tumor size. This has prompted doctors in a new multi-center pilot clinical trial to see...